Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
| Beam Inc. (NASDAQ: BEAM) | Delayed: 25.67 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.67 | 52 Week High | $83.60 | |||
| Open | $25.67 | 52 Week Low | $82.96 | |||
| Day High | $25.67 | P/E | 11.46 | |||
| Day Low | $25.67 | EPS | $2.24 | |||
| Volume | 3,280 | |||||
